Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-Severe Lower Limb Post-Amputation Stump Pain.

Next Previous
X
Search
Trial Profile

Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-Severe Lower Limb Post-Amputation Stump Pain.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 2 PX (Primary)
  • Indications Neuropathic pain; Phantom limb pain
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 Aug 2010 Status changed from recruiting to completed, as reported by the European Clinical Trials Database.
    • 25 Mar 2010 Planned end date changed from Apr 2010 to Jun 2010 as reported by ClinicalTrials.gov.
    • 12 Dec 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top